<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>While the most frequent, surgery for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> is avoided in patients with <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> to the regional lymph nodes (stage III) or distant ones (stage IV) </plain></SENT>
<SENT sid="1" pm="."><plain>Hence, it is being increasingly substituted with neoadjuvant treatment </plain></SENT>
<SENT sid="2" pm="."><plain>Our investigation is concerned with prospective evaluation of the efficacy and toxicity profile of <z:chebi fb="0" ids="31348">capecitabine</z:chebi> (XELODA) in combination with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> (XELOX) and adjuvant Mayo treatment (stage IIb-III) </plain></SENT>
<SENT sid="3" pm="."><plain>Patients had undergone radical surgery (somatic status &lt; or = 2-ECOG) </plain></SENT>
<SENT sid="4" pm="."><plain>The prospective group (166) received 8 courses of adjuvant polychemotherapy (XELOX); the retrospective (2001-2005) one (152)--6 (Mayo) </plain></SENT>
<SENT sid="5" pm="."><plain>The groups matched one another as far as number, gender, age and <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> localization are concerned </plain></SENT>
<SENT sid="6" pm="."><plain>Regional lymph node involvement in group 1 was 64.5%; group 2--59.8% </plain></SENT>
<SENT sid="7" pm="."><plain>Lympho-vascular invasion by <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> was typical of group 1; gastrointestinal toxicity - 9.2% (Mayo) vs. 7.2% in group 1 </plain></SENT>
<SENT sid="8" pm="."><plain>Hematological complications were 5.4% (XELOX) and 5.3% (Mayo); <z:hpo ids='HP_0001875'>neutropenia</z:hpo>-- 5.0% (Mayo) and 3.0% (XELOX); polyneutropenia-- 3.6% (XELOX); <z:chebi fb="0" ids="31348">capecitabine</z:chebi>-related <z:e sem="disease" ids="C0030360" disease_type="Disease or Syndrome" abbrv="PLS">Papillon-Lefevre syndrome</z:e>-- 8.4% </plain></SENT>
<SENT sid="9" pm="."><plain>Three-year relapse-free survival was 53.0% (XELOX) and 47.5 % (Mayo) </plain></SENT>
<SENT sid="10" pm="."><plain>After adjuvant treatment, toxicity profile with XELOX was lower than that after Mayo, with the survival tending to improve </plain></SENT>
</text></document>